Natick, MA, United States of America

Lawrence Charnas

USPTO Granted Patents = 10 


 

Average Co-Inventor Count = 8.1

ph-index = 4

Forward Citations = 44(Granted Patents)


Company Filing History:


Years Active: 2015-2025

Loading Chart...
Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents

Title: The Innovations of Lawrence Charnas: A Pioneer in CNS Therapeutics

Introduction

Lawrence Charnas is a distinguished inventor based in Natick, MA, USA, known for his significant contributions to the field of central nervous system (CNS) therapeutics. With a remarkable portfolio of nine patents, Charnas has been at the forefront of developing innovative methods and compositions aimed at treating lysosomal storage diseases.

Latest Patents

Among Charnas's latest patents are pivotal innovations focused on CNS delivery of therapeutic agents. One notable patent titled "Methods and compositions for CNS delivery of arylsulfatase A" details compositions and methods designed for the delivery of lysosomal enzymes to the central nervous system. This stable formulation allows for direct intrathecal administration of arylsulfatase A (ASA), thereby offering an effective treatment for Metachromatic Leukodystrophy Disease. Additionally, his patent "CNS delivery of therapeutic agents" outlines a less invasive technique for delivering therapeutic agents directly to the CNS, emphasizing methods for administering replacement enzymes for lysosomal enzymes to individuals suffering from associated storage diseases.

Career Highlights

Charnas has been affiliated with prominent companies in the biotechnology sector, notably Shire Human Genetic Therapies, Inc. and Synageva Biopharma Corporation. His tenure at these organizations has been marked by his commitment to advancing therapeutic options for patients affected by complex genetic disorders.

Collaborations

Throughout his career, Lawrence Charnas has collaborated with esteemed professionals in the field, including Pericles Calias and Jing Pan. These collaborations have fostered an environment of innovation, contributing to the development of cutting-edge therapies aimed at improving patient outcomes.

Conclusion

Lawrence Charnas's work exemplifies a steadfast dedication to innovation in the realm of CNS therapeutics. His patents not only reflect his inventive spirit but also his commitment to addressing critical medical challenges faced by individuals with lysosomal storage diseases. As he continues to develop new approaches and methods, the impact of his contributions is likely to resonate in the medical community for years to come.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…